As the most effective antigen-presenting cells, DCs have long been considered a crucial factor in antitumour immunotherapy since they can efficiently activate T lymphocyte-mediated antitumour activity by processing and presenting tumour antigens to CD4+ or CD8+ T cells via major histocompatibility complex (MHC) class II or class I molecules, respectively [8]. This evidence concerns the gene CD8A and neoplasm.